Related Experiment Video
Updated: Apr 9, 2026

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
Published on: November 17, 2015
Nanoparticle technologies for liver targeting and their applications in liver diseases
Mengjia Peng1,2,3, Fei Fang1, Bowen Wang1,2,3
1Department of Emergency, The General Hospital of Tibet Military Command, Lhasa, China.
None:
Liver diseases represent a significant global health challenge, affecting millions of lives annually. The advent of nanoparticle (NP) technologies has introduced promising therapeutic strategies for addressing liver diseases. Given the liver's pivotal role in detoxification and the inherent ability to interact with circulating NPs, it emerges as an ideal target for NP-mediated therapies. Upon systemic administration, NPs predominantly accumulate within the liver, where they are uptaken and internalized by hepatic macrophages, sinusoidal endothelial cells, and hepatocytes. This natural tropism of NPs toward the liver highlights their potential for targeted liver disease management. This review describes the physiological conditions of the hepatic sinusoids and elucidates the interactions between various hepatic cells and NPs. A thorough understanding of these physiological mechanisms is essential for optimizing liver-targeted NP delivery systems, thereby improving NP accumulation at pathological sites. The development of liver-targeted NPs technologies holds immense promise for both the diagnosis and treatment of liver diseases.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers

